Specialist in mechanical resonance imaging (MRI) equipment, Iradimed, experienced a notable boost in its stock value, rising over 4% on Friday following a strong quarterly earnings report. This significant increase outstripped the S&P 500 index, which managed only a 0.3% gain during the same trading session.
The company’s quarterly figures revealed a 13% revenue increase, bringing its top-line earnings close to $22 million, surpassing analyst expectations of $20.8 million. Iradimed’s profitability also impressed investors as its net income rose by 24%, exceeding $5.8 million. On a per-share basis, adjusted earnings (non-GAAP) climbed 17% to $0.49, again beating analyst forecasts which estimated earnings of $0.46 per share.
Revenue from MRI system devices was the standout performer, contributing almost $15.4 million to the company’s earnings with a remarkable 19% increase. The MRI-compatible intravenous (IV) infusion pump devices were highlighted as the most successful products in this category.
In its earnings announcement, Iradimed expressed optimism regarding the launch of its latest IV pump system, the 3870, which debuted during the quarter. CEO Roger Susi remarked on the positive customer response, noting “tremendous interest and strong early order activity” for the new device.
Looking ahead, Iradimed reaffirmed its revenue guidance for the year, projecting an estimated $91 million to $96 million, alongside an adjusted earnings per share forecast of $2.06 to $2.21. As the aging population increases both in the U.S. and globally, the demand for medical care is set to rise, positioning well-managed and profitable niche medical device manufacturers favorably in the market.
With its robust performance and positive outlook, many analysts believe investing in Iradimed presently is a wise decision.
